NCT02445053View on ClinicalTrials.gov

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions

Cystic Fibrosis

Interventions

DRUG

ivacaftor

Trial Locations (15)

Unknown

Bari

Messina

Milan

Naples

Potenza

Verona

The Hague

Amsterdam

Gronningen

Heidelberglaan

Nijmegen

Rotterdam

London

Birmingham

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02445053 - Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) | Biotech Hunter | Biotech Hunter